High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis.

第3相 完了 NCT06381076

概要

A 12-week double-blind randomized control trial will be conducted among adults on hemodialysis (n=15) to determine the impact of liposomal curcumin in a high-protein product on inflammation markers and oxidative stress. Participants will be randomized via a computer-generator into either the control or intervention group. Participants in each group will be given a total of 38 g of a high protein product with or without 7 mls of liposomal curcumin for a total of 8 weeks. At baseline, weeks 8 and 12, participants will have blood sampled and complete a 3-day 24-hour recalls (2 non-dialysis days and 1 dialysis day) and a quality of life survey.

High-sensitivity C-reactive Protein

12 weeks or 84 days · milligrams per liter (mg/L)

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoieti — GlaxoSmithKline
• Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
• Bone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine
• Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients — The University of Texas at Arlington
• Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver F — Genfit
• Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects Wi — Novartis Pharmaceuticals

すべての治験